CRIS Current Research Information System

BISELLI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.721
AS - Asia 5.410
EU - Europa 3.779
AF - Africa 323
SA - Sud America 252
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.496
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.674
VN - Vietnam 1.980
SG - Singapore 1.292
CN - Cina 1.076
IT - Italia 788
GB - Regno Unito 732
SE - Svezia 506
DE - Germania 470
HK - Hong Kong 348
IN - India 248
FR - Francia 231
BR - Brasile 164
IE - Irlanda 164
NL - Olanda 161
RU - Federazione Russa 160
UA - Ucraina 131
CH - Svizzera 116
TG - Togo 100
JO - Giordania 81
KR - Corea 76
ZA - Sudafrica 75
FI - Finlandia 72
JP - Giappone 68
CI - Costa d'Avorio 67
EE - Estonia 53
BG - Bulgaria 46
TH - Thailandia 41
AT - Austria 35
PH - Filippine 35
SC - Seychelles 29
BD - Bangladesh 27
BE - Belgio 26
AR - Argentina 25
ID - Indonesia 23
IR - Iran 23
CA - Canada 21
NG - Nigeria 20
EC - Ecuador 19
ES - Italia 17
PL - Polonia 17
CL - Cile 15
MX - Messico 14
TW - Taiwan 14
HR - Croazia 13
PK - Pakistan 13
IQ - Iraq 12
TR - Turchia 11
CO - Colombia 10
ET - Etiopia 10
UZ - Uzbekistan 9
VE - Venezuela 8
AU - Australia 7
LT - Lituania 7
SA - Arabia Saudita 7
LB - Libano 5
MA - Marocco 5
MY - Malesia 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
PT - Portogallo 4
PY - Paraguay 4
RO - Romania 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
EG - Egitto 3
GR - Grecia 3
MK - Macedonia 3
NP - Nepal 3
UY - Uruguay 3
BO - Bolivia 2
CG - Congo 2
EU - Europa 2
IL - Israele 2
LU - Lussemburgo 2
MM - Myanmar 2
MU - Mauritius 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CM - Camerun 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
KZ - Kazakistan 1
LV - Lettonia 1
MT - Malta 1
Totale 15.490
Salva come PNG Salva come JPEG
Città #
Singapore 884
Ashburn 628
Southend 628
Fairfield 590
Chandler 510
Ho Chi Minh City 423
Dong Ket 415
Hanoi 380
Hong Kong 309
Bologna 291
Woodbridge 286
Houston 277
Seattle 264
San Jose 254
Wilmington 223
Cambridge 208
Santa Clara 185
Princeton 172
Dublin 162
Ann Arbor 154
Hefei 153
Beijing 126
Boardman 111
Bern 105
Lomé 100
Lauterbourg 85
Amman 80
Jacksonville 79
Da Nang 76
Los Angeles 76
Dallas 73
Redmond 70
Abidjan 67
Westminster 66
New York 61
Milan 60
Padova 57
Seoul 57
Tokyo 57
Berlin 56
Haiphong 54
Helsinki 54
Nanjing 51
Shenyang 44
Sofia 43
Buffalo 41
Munich 41
Jinan 40
Council Bluffs 38
Florence 36
San Diego 36
Amsterdam 31
Frankfurt am Main 31
Saint Petersburg 31
Turin 31
Rome 30
Guangzhou 28
Hải Dương 27
Vienna 27
Brussels 26
Redondo Beach 26
Tianjin 26
Bremen 25
Falkenstein 23
Nanchang 23
Shanghai 23
Hebei 22
São Paulo 22
Des Moines 21
Bến Tre 20
Changsha 20
London 20
Abeokuta 19
Hangzhou 19
Biên Hòa 18
Can Tho 17
Chicago 16
Medford 16
Paris 16
Phoenix 16
Zhengzhou 16
Johannesburg 15
Mülheim 15
Dearborn 14
The Dalles 14
Wuhan 14
Bangkok 13
Bengaluru 13
Bắc Ninh 13
Norwalk 13
Vũng Tàu 13
Washington 13
Brooklyn 12
Falls Church 12
Jiaxing 12
Nha Trang 12
Olalla 12
Turku 12
Mahé 11
Orem 11
Totale 10.266
Salva come PNG Salva come JPEG
Nome #
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 303
Monofocal hepatocellular carcinoma: How much does size matter? 283
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 280
Optimization of pineapple juice amount used as a negative oral contrast agent in magnetic resonance cholangiopancreatography 274
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 260
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 249
Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. 246
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 239
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 236
Pattern of macrovascular invasion in hepatocellular carcinoma 233
Chronic prostatitis/pelvic pain syndrome: MRI findings and clinical correlations. 231
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 230
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 225
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 224
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 218
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 216
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 216
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 215
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 213
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 209
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 208
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 205
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 204
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 203
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 201
The changing scenario of hepatocellular carcinoma in Italy: an update 200
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 197
Metabolic disorders across hepatocellular carcinoma in Italy 193
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 192
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 189
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 188
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 186
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 186
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 184
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 182
Liver transplantation for patients with alcoholic liver disease: an open question 180
Posttranscriptional changes of serum albumin: clinical and prognostic meaning in hospitalized patients with cirrhosis. 180
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned. 178
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 178
What is the best fruit juice to use as a negative oral contrast agent in magnetic resonance cholangiopancreatography? 177
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 172
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 170
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 169
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 169
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 168
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 168
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 167
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 167
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 165
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 165
null 164
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 158
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma 158
Trattamento dell’epatopatia alcolica 157
Years of life that could be saved from prevention of hepatocellular carcinoma. 155
New MRI series for kidney evaluation: Saving time and money 154
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 151
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 149
Magnetic Resonance Enterography Reinvented: Exploring the Potential of a New Natural Beverage as an Alternative to Polyethylene Glycol Solution 148
Reply to “Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis” 148
The Gastropack Access System as a Model to Access Gastroenterology Services for Gastroscopy Appropriateness in Patients with Upper Gastrointestinal Symptoms: A Comparison with the Open Access System 147
The MELD score in patients awaiting liver transplant: strengths and weaknesses. 147
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 145
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 144
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 144
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 141
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 140
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 140
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 136
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 134
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 132
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 124
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 120
Hepatocellular carcinoma surveillance: an open question 118
null 117
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 116
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. 113
Liver injury with novel oral anticoagulants: Assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system 113
Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection. 107
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 106
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 97
null 95
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 86
null 83
Prognosis of untreated hepatocellular carcinoma. 78
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? 74
null 72
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma 70
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 67
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 66
A modified Child-Turcotte-Pugh (CTP) for selection of candidates to liver transplantation (LT) with low model for end-stage liver disease score (MELD). 65
A modified Child-Turcotte-Pugh (CTP) for selection of patients affected by cirrhosis candidates for liver transplantation (LT) with low model for end-stage liver disease score (MELD) 63
Seven score systems to evaluate candidates to orthotopic liver transplantation: which is the winner? 60
Natremia and Child-Turcotte-Pugh (CTP) score may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD) 53
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 49
Natremia and Child-Turcotte-Pugh (CTP) may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD). 46
Totale 15.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021706 0 0 0 0 0 0 0 0 0 72 63 571
2021/20221.849 133 83 81 153 138 101 45 145 66 145 491 268
2022/20232.136 194 338 99 286 113 179 79 105 360 66 160 157
2023/2024621 64 87 45 50 48 131 21 61 28 31 35 20
2024/20252.016 80 286 179 179 277 110 192 71 15 175 97 355
2025/20265.066 362 370 412 314 491 279 1.139 211 1.105 383 0 0
Totale 15.749